日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Safety and efficacy of cabozantinib for patients with advanced hepatocellular carcinoma who advanced to Child-Pugh B liver function at study week 8: a retrospective analysis of the CELESTIAL randomised controlled trial

卡博替尼治疗在研究第 8 周时进展为 Child-Pugh B 级肝功能的晚期肝细胞癌患者的安全性和有效性：CELESTIAL 随机对照试验的回顾性分析

期刊:BMC Cancer
影响因子:3.4
doi:10.1186/s12885-022-09453-z
El-Khoueiry, Anthony B; Meyer, Tim; Cheng, Ann-Lii; Rimassa, Lorenza; Sen, Suvajit; Milwee, Steven; Kelley, Robin Kate; Abou-Alfa, Ghassan K
CEL
细胞生物学
肿瘤
肿瘤免疫
发表日期：2022
文献求助 收藏

Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial

索拉非尼治疗后二线卡博替尼治疗晚期肝细胞癌：CELESTIAL III期试验的亚组分析

期刊:ESMO Open
影响因子:8.3
doi:10.1136/esmoopen-2020-000714
Kelley, Robin Kate; Ryoo, Baek-Yeol; Merle, Philippe; Park, Joong-Won; Bolondi, Luigi; Chan, Stephen L; Lim, Ho Yeong; Baron, Ari D; Parnis, Francis; Knox, Jennifer; Cattan, Stéphane; Yau, Thomas; Lougheed, Julie C; Milwee, Steven; El-Khoueiry, Anthony B; Cheng, Ann-Lii; Meyer, Tim; Abou-Alfa, Ghassan K
CEL
细胞生物学
肿瘤
肿瘤免疫
发表日期：2020
文献求助 收藏

Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial

卡博替尼：晚期肾细胞癌骨转移患者的新标准治疗方案？METEOR试验的亚组分析

期刊:Journal of Clinical Oncology
影响因子:41.9
doi:10.1200/JCO.2017.74.7352
Escudier, Bernard; Powles, Thomas; Motzer, Robert J; Olencki, Thomas; Arén Frontera, Osvaldo; Oudard, Stephane; Rolland, Frederic; Tomczak, Piotr; Castellano, Daniel; Appleman, Leonard J; Drabkin, Harry; Vaena, Daniel; Milwee, Steven; Youkstetter, Jillian; Lougheed, Julie C; Bracarda, Sergio; Choueiri, Toni K
肿瘤
肿瘤免疫
肾癌
细胞生物学
MET
发表日期：2018
文献求助 收藏